Financial Advantage, Inc. recently filed their 13F report for the second quarter of 2022, which ended on 2022-06-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
10211 Wincopin Circle Columbia, MD 21044
As of the latest 13F report, the guru’s equity portfolio contained 124 stocks valued at a total of $109.00Mil. The top holdings were GLD(9.57%), IGV(7.59%), and BMY(6.00%).
According to GuruFocus data, these were Financial Advantage, Inc.’s top five trades of the quarter.
CarMax Inc
The guru established a new position worth 26,230 shares in NYSE:KMX, giving the stock a 2.05% weight in the equity portfolio. Shares traded for an average price of $107.63 during the quarter.
On 08/01/2022, CarMax Inc traded for a price of $101.96 per share and a market cap of $16.23Bil. The stock has returned -23.88% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, CarMax Inc has a price-earnings ratio of 17.30, a price-book ratio of 3.02, a price-earnings-to-growth (PEG) ratio of 1.26, a EV-to-Ebitda ratio of 18.90 and a price-sales ratio of 0.49.
The price-to-GF Value ratio is 0.59, earning the stock a GF Value rank of 8.
SPDR Biotech ETF
During the quarter, Financial Advantage, Inc. bought 22,482 shares of ARCA:XBI for a total holding of 35,523. The trade had a 1.63% impact on the equity portfolio. During the quarter, the stock traded for an average price of $92.34.
On 08/01/2022, SPDR Biotech ETF traded for a price of $79.47 per share and a market cap of $7.44Bil. The stock has returned -35.60% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, SPDR Biotech ETF has a price-book ratio of 3.13.
Apple Inc
During the quarter, Financial Advantage, Inc. bought 3,692 shares of NAS:AAPL for a total holding of 5,135. The trade had a 0.52% impact on the equity portfolio. During the quarter, the stock traded for an average price of $168.23.
On 08/01/2022, Apple Inc traded for a price of $161.51 per share and a market cap of $2,595.59Bil. The stock has returned 11.34% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, Apple Inc has a price-earnings ratio of 26.24, a price-book ratio of 38.84, a price-earnings-to-growth (PEG) ratio of 1.85, a EV-to-Ebitda ratio of 20.06 and a price-sales ratio of 6.94.
The price-to-GF Value ratio is 0.96, earning the stock a GF Value rank of 6.
Caterpillar Inc
The guru established a new position worth 1,965 shares in NYSE:CAT, giving the stock a 0.35% weight in the equity portfolio. Shares traded for an average price of $209.75 during the quarter.
On 08/01/2022, Caterpillar Inc traded for a price of $194.86 per share and a market cap of $103.93Bil. The stock has returned -3.56% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Caterpillar Inc has a price-earnings ratio of 16.33, a price-book ratio of 6.09, a price-earnings-to-growth (PEG) ratio of 0.89, a EV-to-Ebitda ratio of 12.29 and a price-sales ratio of 1.99.
The price-to-GF Value ratio is 0.97, earning the stock a GF Value rank of 6.
Eli Lilly and Co
The guru sold out of their 1,000-share investment in NYSE:LLY. Previously, the stock had a 0.23% weight in the equity portfolio. Shares traded for an average price of $256.89 during the quarter.
On 08/01/2022, Eli Lilly and Co traded for a price of $324.15 per share and a market cap of $307.99Bil. The stock has returned 34.62% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Eli Lilly and Co has a price-earnings ratio of 48.66, a price-book ratio of 33.03, a price-earnings-to-growth (PEG) ratio of 2.52, a EV-to-Ebitda ratio of 37.00 and a price-sales ratio of 10.07.
The price-to-GF Value ratio is 1.55, earning the stock a GF Value rank of 1.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
